AR099220A1 - (hetero)aril-imidazoles / pirazoles, métodos para su preparación, composición farmacéutica que lo contiene y su empleo en el tratamiento de enfermedades mediadas por la inhibición de pde10a - Google Patents

(hetero)aril-imidazoles / pirazoles, métodos para su preparación, composición farmacéutica que lo contiene y su empleo en el tratamiento de enfermedades mediadas por la inhibición de pde10a

Info

Publication number
AR099220A1
AR099220A1 ARP150100251A ARP150100251A AR099220A1 AR 099220 A1 AR099220 A1 AR 099220A1 AR P150100251 A ARP150100251 A AR P150100251A AR P150100251 A ARP150100251 A AR P150100251A AR 099220 A1 AR099220 A1 AR 099220A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
treatment
pde10a
chosen
Prior art date
Application number
ARP150100251A
Other languages
English (en)
Inventor
Flohr Alexander
Groebke Zbinden Katrin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR099220A1 publication Critical patent/AR099220A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Estos compuestos poseen actividad inhibitoria de PDE10A y ser utilizado por lo tanto para el tratamiento de enfermedades psicóticas tales como la esquizofrenia. Reivindicación 1: Un compuesto que tiene la fórmula (1), en la que: A es un compuesto de fórmula (2); R¹ se elige entre arilo y heteroarilo; R² se elige entre hidrógeno y alquilo C₁₋₇; R³ se elige entre hidrógeno y alquilo C₁₋₇; R⁴ se elige entre hidrógeno, alquilo C₁₋₇, alcoxi C₁₋₇ y C(O)NRR; R y R se eligen con independencia entre hidrógeno y alquilo C₁₋₇; R⁵ se elige entre alquilo C₁₋₇, cicloalquilo C₃₋₈, haloalquilo C₁₋₇, ciano, hidroxialquilo C₁₋₇ y C(O)NRR; R y R se eligen con independencia entre hidrógeno y alquilo C₁₋₇; R⁶ se elige entre hidrógeno, alquilo C₁₋₇ e hidroxialquilo C₁₋₇; o R⁵ y R⁶ juntos forman un cicloalquilo C₃₋₈; X e Y se eligen con independencia entre C y N, con la condición de que X e Y no sean simultáneamente N; Z se elige entre CH y N; B se elige entre alquileno C₁₋₄, alquenileno C₂₋₄, alquinileno C₂₋₄ y -O-alquilo C₁₋₄.
ARP150100251A 2014-01-31 2015-01-29 (hetero)aril-imidazoles / pirazoles, métodos para su preparación, composición farmacéutica que lo contiene y su empleo en el tratamiento de enfermedades mediadas por la inhibición de pde10a AR099220A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14153372 2014-01-31

Publications (1)

Publication Number Publication Date
AR099220A1 true AR099220A1 (es) 2016-07-06

Family

ID=50028897

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100251A AR099220A1 (es) 2014-01-31 2015-01-29 (hetero)aril-imidazoles / pirazoles, métodos para su preparación, composición farmacéutica que lo contiene y su empleo en el tratamiento de enfermedades mediadas por la inhibición de pde10a

Country Status (12)

Country Link
US (1) US10399985B2 (es)
EP (1) EP3099690B1 (es)
JP (1) JP6471169B2 (es)
KR (1) KR20160108561A (es)
CN (1) CN105899513A (es)
AR (1) AR099220A1 (es)
CA (1) CA2935065A1 (es)
HK (1) HK1223932A1 (es)
MX (1) MX2016009448A (es)
RU (1) RU2016133624A (es)
TW (1) TW201613924A (es)
WO (1) WO2015113980A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
WO2010063487A1 (en) * 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
TW201200516A (en) * 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2013052526A1 (en) * 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. Triazolyl pde10 inhibitors
WO2013127817A1 (en) * 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
EP2916842B1 (en) * 2012-11-07 2016-10-19 F. Hoffmann-La Roche AG Triazolo compounds

Also Published As

Publication number Publication date
KR20160108561A (ko) 2016-09-19
WO2015113980A1 (en) 2015-08-06
US20160333018A1 (en) 2016-11-17
EP3099690B1 (en) 2019-08-28
EP3099690A1 (en) 2016-12-07
CA2935065A1 (en) 2015-08-06
TW201613924A (en) 2016-04-16
US10399985B2 (en) 2019-09-03
HK1223932A1 (zh) 2017-08-11
CN105899513A (zh) 2016-08-24
JP2017504648A (ja) 2017-02-09
JP6471169B2 (ja) 2019-02-13
RU2016133624A (ru) 2018-03-06
MX2016009448A (es) 2016-10-13

Similar Documents

Publication Publication Date Title
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR106099A1 (es) Compuestos bicíclicos como inhibidores duales de atx / ca
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
AR122049A2 (es) Derivados de pirimidiniloxi benceno como herbicidas
AR096684A1 (es) Compuestos para tratar atrofia muscular espinal
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
TR201900038T4 (tr) GPR6'nın tetrahidropiridopirazin modülatörleri.
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR095347A1 (es) Compuestos orgánicos
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR090967A1 (es) Picolinamidas macrociclicas como fungicidas
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
BR112015018509A2 (pt) compostos de imidazo piridina
AR097866A1 (es) Derivados de 4-azaindol
AR106100A1 (es) Compuestos bicíclicos como inhibidores duales atx / ca
AR099415A1 (es) Benzoilfenil-formamidinas con actividad fungicida, sus composiciones agronómicas y su uso para el control de hongos fitopatogénicos de cultivos agrarios
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR097253A1 (es) Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida
AR101255A1 (es) Derivados de isoindolinona
AR100776A1 (es) Compuestos herbicidas
AR093758A1 (es) Inhibidores de aril lactama quinasa
AR101479A1 (es) Derivados de 6-alquinil-piridina

Legal Events

Date Code Title Description
FB Suspension of granting procedure